Home/NGM Biopharmaceuticals/John V. Gray, Ph.D.
JV

John V. Gray, Ph.D.

President of Research & Chief Scientific Officer

NGM Biopharmaceuticals

NGM Biopharmaceuticals Pipeline

DrugIndicationPhase
NGM120Hyperemesis GravidarumPhase 2
NGM831 (MK-3655)Metabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 2b
NGM621Geographic Atrophy (GA)Phase 2
NGM438Genetic LipodystrophyPreclinical